NeuroOne Medical Technologies Corp [NMTC] stock prices are up 0.72% to $0.83 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NMTC shares have gain 11.31% over the last week, with a monthly amount glided 32.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NeuroOne Medical Technologies Corp [NASDAQ: NMTC] stock has seen the most recent analyst activity on March 29, 2022, when Craig Hallum downgraded its rating to a Hold and also revised its price target to $2 from $6.
The stock price of NeuroOne Medical Technologies Corp [NMTC] has been fluctuating between $0.55 and $1.68 over the past year. NeuroOne Medical Technologies Corp [NASDAQ: NMTC] shares were valued at $0.83 at the most recent close of the market.
Analyzing the NMTC fundamentals
The NeuroOne Medical Technologies Corp [NASDAQ:NMTC] reported sales of 3.45M for trailing twelve months, representing a drop of -63.29%. Gross Profit Margin for this corporation currently stands at 0.31% with Operating Profit Margin at -3.44%, Pretax Profit Margin comes in at -3.57%, and Net Profit Margin reading is -3.57%. To continue investigating profitability, this company’s Return on Assets is posted at -2.29, Equity is -4.07 and Total Capital is -3.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7969 points at the first support level, and at 0.7680 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8519, and for the 2nd resistance point, it is at 0.8780.
Ratios To Look Out For
It’s worth pointing out that NeuroOne Medical Technologies Corp [NASDAQ:NMTC]’s Current Ratio is 2.03. Also, the Quick Ratio is 0.84, while the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 7.38, the price to book ratio is 30.97.
Transactions by insiders
Recent insider trading involved Christianson Mark, Business Development Director, that happened on Jun 06 ’24 when 2189.0 shares were sold. Business Development Director, Christianson Mark completed a deal on Jun 05 ’24 to sell 25800.0 shares.
